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Conclusions: Treatment patterns following the diagnosis of breast cancer varied with age and
surgery type. Younger women were more likely to receive mastectomy, chemotherapy, and
breast reconstruction than older women. Younger women and women who underwent
mastectomy had higher average overall health care costs within 1 year of surgical treatment.
Table: Procedure rates among women with newly diagnosed breast cancer by age at diagnosis
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Background/Objective: Current National Comprehensive Cancer Network (NCCN) guidelines
recommend modified radical mastectomy (MRM) as the surgical treatment of choice for nonmetastatic inflammatory breast cancer (IBC). Using data from the National Cancer Database
(NCDB), our study compared the national trends and outcomes of breast-conserving surgery
(BCS) vs. MRM for the treatment of IBC.
Methods: NCDB data from 2004 to 2014 were retrospectively analyzed. Patients’
demographics, tumor characteristics, and overall mortality (OM) trends were compared between
BCS and MRM cases of IBC. Univariate, multivariate, and propensity score weighted analyses
were done to compare study groups and build a predictive model for undergoing BCS.
400

Results: A total of 445 (4.01%) BCS and 10,645 (95.99%) MRM cases were identified. Median
follow-up was 58.48 months. Compared to MRM, BCS patients were more likely to be older
(Mean:61, SD:15.4 vs. Mean:56, SD:12.9- p<0.001), non-White race, have Medicare, or be uninsured, and less educated. BCS tumors were more likely to be ER+/PR+/HER2+ and diagnosed
at Stage I (5-6.25% vs 75-93.75%) or II (23-6.67% vs. 322-93.33%) than Stage III (417-3.91%
vs. 10,248-96.06%), p<0.05. BCS rates significantly decreased from 6.16% in 2004 to 3.64% in
2014 (p<0.001). Significant predictors of BCS include older age, treatment at academic
programs, non-White race, metropolitan county residence, Stage II disease, and a tumor primary
site of the nipple, lower inner or outer quadrants, or axillary tail (all p<0.05). Ninety-day OM
(4.84% vs 1.60%), and 30-day readmission (5.17% vs 3.81%) were significantly higher in BCS
cases (p<0.05). In the adjusted stage-stratified propensity score weighted analysis, Stage III BCS
had a 51% higher hazard of OM compared to MRM (HR:1.51; p<0.001), while no difference in
OM was found for Stage I (HR:0.45; p=0.42) and II (HR:1.13; p=0.42) cases.
Conclusions: BCS was done in a few number of cases. The adjusted analysis showed an
associated significant OM with Stage III BCS but not Stages I and II. These data further support
adhering to current MRM treatment guidelines.
769349 - Encapsulated Papillary Carcinoma of the Breast. Experience of 58 Cases in Our
Local Institution and Review of the Literature
Hiang Jin Tan1, Puay Hoon Tan2, Benita Kiat Tee Tan1, Sue Zann Lim1, Preetha Madhukumar1,
Veronique Kiak Mien Tan1, Chow Yin Wong1, Wei Sean Yong1, Yi Rong Sim1
1
SingHealth Duke-NUS Breast Centre, Singapore, 2Singapore General Hospital, Singapore
Background/Objective: Encapsulated papillary carcinoma of the breast (EPC) is a rare entity of
breast cancer accounting for 0.5-1% of breast cancer. It is often difficult to diagnose on core
biopsy, resulting in several patients requiring an excision biopsy before definitive surgery. There
is limited evidence-based guidelines on the management of EPC. The aim of this study is to
further elucidate the clinic-pathological characteristics, treatment, and survival outcome of this
group of patients.
Methods: A total of 58 patients were diagnosed with EPC from 2014 to 2018, with a median
follow-up duration of 48 months. Patients’ demographics data, radiological, and
clinicopathological characteristics, treatment, adjuvant therapies, as well as survival data were
analysed.
Results: Thirteen (27.1%) patients required excision biopsy because core biopsy results were
inconclusive, and histology often returned as hematoma. Common radiological features of EPCs
were mixed solid cystic mass lesion with increased vascularity in the solid lesions. Twenty-five
(43.1%) cases were pure EPC, 15 (25.9%) were EPC associated with ductal carcinoma in situ
(DCIS), and 18 (31.0%) cases had concurrent invasive ductal carcinoma (IDC). Median tumour
size was largest in the EPC with IDC group, which was 25mm, followed by the pure EPC group
(16mm) and EPC with DCIS (10mm). Forty-seven patients (81.0%) had positive estrogen and
progesterone receptor (ER/PR) status in all subgroups, and only 3 patients were HER2 receptor401

